Copies of letters sent to healthcare professionals in December 2012, to inform of new safety information and advice:


Date sent Medicine Safety information
3 December 2012 Sprayable Evicel fibrin sealantPDF file (opens in new window) (94Kb) Risk of life-threatening air embolism.
10 December 2012 Lapatinib (Tyverb)PDF file (opens in new window) (674Kb) Lapatinib combined with capecitabine has poorer efficacy compared with trastuzumab combined with capecitabine.
10 December 2012 Lenalidomide (Revlimid)PDF file (opens in new window) (38Kb) Risk of hepatic disorders – routine monitoring of liver function, and dose adjustments in patients with renal impairment, are recommended.







Posted on the UK MHRA website on 3 January 2013